SSY Group Secures Approval for New Respiratory Drugs

SSY Group ( (HK:2005) ) just unveiled an announcement.

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two drugs: Diprophylline Injection and Formoterol Fumarate Inhalation Solution. These approvals enhance the company’s portfolio in respiratory treatments, potentially strengthening its market position and offering new options for patients with conditions like asthma and COPD.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating treatments for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

YTD Price Performance: -20.41%

Average Trading Volume: 13,076,849

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.12B

See more insights into 2005 stock on TipRanks’ Stock Analysis page.